<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently, American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association (<z:chebi fb="36" ids="39048">ADA</z:chebi>) and European Association for the Study of <z:mp ids='MP_0002055'>Diabetes</z:mp> (EASD) as well as International <z:mp ids='MP_0002055'>Diabetes</z:mp> Federation (IDF) have <z:hpo ids='HP_0000001'>all</z:hpo> issued their recommendations on the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the same objectives, these guidelines are substantially different in terms of target values of <z:chebi fb="105" ids="17234">glucose</z:chebi> control, strategies for drug choice etc </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="36" ids="39048">ADA</z:chebi>/EASD guidelines offer practical algorithm to help initiate and modify pharmacological therapy for <z:mp ids='MP_0002055'>diabetes</z:mp>, with detailed descriptions of treatment options </plain></SENT>
<SENT sid="3" pm="."><plain>IDF document, however, concentrates on the role of <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> and calls for lower HbA1c target value of 6.5% as opposed to <z:chebi fb="36" ids="39048">ADA</z:chebi>/EASD guidelines advocating value of 7% </plain></SENT>
<SENT sid="4" pm="."><plain>Careful analysis of the guidelines contents suggests that <z:chebi fb="36" ids="39048">ADA</z:chebi>/EASD consensus might be more useful in everyday clinical practice than IDF recommendations, which do not offer a particular treatment algorithm </plain></SENT>
</text></document>